Cristian P. Moiola

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

A mouse PDX clinical trial reveals broad efficacy of niraparib and vc-seco-DUBA anti-HER2 ADC SYD985 in HER2/neu expressing endometrial cancer.

A mouse PDX clinical trial reveals broad efficacy of niraparib and vc-seco-DUBA anti-HER2 ADC SYD985 in HER2/neu expressing endometrial cancer.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: May 07, 2026

Role of cfDNA and ctDNA to improve the risk stratification and the disease follow-up in patients with endometrial cancer: towards the clinical application.

Role of cfDNA and ctDNA to improve the risk stratification and the disease follow-up in patients with endometrial cancer: towards the clinical application.

Journal: Journal of experimental & clinical cancer research : CR

Published: June 09, 2024

Corrigendum: FXYD5/Dysadherin, a biomarker of endometrial cancer myometrial invasion and aggressiveness: its relationship with TGF-β1 and NF-κB pathways.

Corrigendum: FXYD5/Dysadherin, a biomarker of endometrial cancer myometrial invasion and aggressiveness: its relationship with TGF-β1 and NF-κB pathways.

Journal: Frontiers in oncology

Published: October 18, 2023

Endometrial cancer PDX-derived organoids (PDXOs) and PDXs with FGFR2c isoform expression are sensitive to FGFR inhibition.

Endometrial cancer PDX-derived organoids (PDXOs) and PDXs with FGFR2c isoform expression are sensitive to FGFR inhibition.

Journal: NPJ precision oncology

Published: January 25, 2023

Noninvasive detection of microsatellite instability in patients with endometrial cancer.

Noninvasive detection of microsatellite instability in patients with endometrial cancer.

Journal: International journal of cancer

Published: October 21, 2022

Genomic Validation of Endometrial Cancer Patient-Derived Xenograft Models as a Preclinical Tool.

Genomic Validation of Endometrial Cancer Patient-Derived Xenograft Models as a Preclinical Tool.

Journal: International journal of molecular sciences

Published: April 25, 2022

The amount of preoperative endometrial tissue surface in relation to final endometrial cancer classification.

The amount of preoperative endometrial tissue surface in relation to final endometrial cancer classification.

Journal: Gynecologic oncology

Published: March 28, 2022

Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression.

Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression.

Journal: Oncogene

Published: May 27, 2021

Modeling ANXA2-overexpressing circulating tumor cells homing and high throughput screening for metastasis impairment in endometrial carcinomas.

Modeling ANXA2-overexpressing circulating tumor cells homing and high throughput screening for metastasis impairment in endometrial carcinomas.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: March 01, 2021

Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer.

Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer.

Journal: Gynecologic oncology

Published: February 20, 2021

Small-Molecule Inhibitors (SMIs) as an Effective Therapeutic Strategy for Endometrial Cancer.

Small-Molecule Inhibitors (SMIs) as an Effective Therapeutic Strategy for Endometrial Cancer.

Journal: Cancers

Published: August 04, 2020

Genomic Profiling of Uterine Aspirates and cfDNA as an Integrative Liquid Biopsy Strategy in Endometrial Cancer.

Genomic Profiling of Uterine Aspirates and cfDNA as an Integrative Liquid Biopsy Strategy in Endometrial Cancer.

Journal: Journal of clinical medicine

Published: January 22, 2020

Showing 1-12 of 28

Last Updated: 09/26/2026